Sangamo launches auction for ST-503 pain program as Chapter 11 asset sales close with $163.55 million proceeds
Bitget2026/10/13 20:01- Sangamo set a fourth-quarter 2026 deadline for an auction of its clinical-stage ST-503 chronic neuropathic pain program.
- Asset sales completed through a court-supervised Section 363 process generated USD 163.55 million in gross cash proceeds.
- PTC bought the Fabry disease program ST-920 for USD 111 million in cash, with up to USD 100 million in milestone payments.
- Lilly acquired Sangamo’s capsid delivery, zinc finger and MINT platforms, with the ST-506 prion disease program, for USD 50 million in cash.
- Proceeds were used to repay all outstanding amounts under the debtor-in-possession financing facility provided by Future Solutions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoJ Koeda: Need to adjust monetary policy appropriately in light of upside price risks
Strong Demand for Mobile Network Equipment: Ericsson (ERIC.US) Q3 Earnings Exceed Expectations, but Component Costs May Suppress Next Year's Gross Margin
Ericsson (ERIC.US) exceeded analysts' expectations for third-quarter earnings, mainly benefiting from strong demand for mobile network equipment in its core market.
Intense debate within the European Central Bank over the endpoint of rate hikes: Economists expect a "final hike" in December, officials say it is nearing the restrictive zone
Primož Dolenc, a member of the European Central Bank's Governing Council, stated that tighter financial conditions may reduce the necessity for the ECB to take monetary policy action.
Crypto prices
More
